文献速递支持与姑息治疗

生命终末期化疗的使用:哪些因素重要?

Use of chemotherapy near the end of life: what factors matter?
PubMed 文献 · Ann Oncol · 2017-01-01

法国2010至2013年基于登记处的全国性研究纳入279846例因转移性实体瘤住院死亡患者,分析生命终末期化疗使用相关因素。临终前1个月内19.5%接受化疗(最后2周内11.3%)。女性、高龄、更多慢性合并症与较低化疗率独立相关;在营利性诊所/医院或综合癌症中心死亡、高容量中心及无姑息治疗病房的医院报告高于平均的终末期化疗率。

要点

  • 临终前1个月内19.5%接受化疗,最后2周内11.3%。
  • 女性、高龄、更多慢性合并症与较低终末期化疗率独立相关。
  • 在营利性机构或综合癌症中心死亡者更可能接受终末期化疗。

核心结论

  • 在住院癌症患者中,年轻个体、在综合癌症中心或无姑息治疗病房的高容量中心治疗者最可能接受终末期化疗。
  • 不同癌症的预期化疗敏感性与患者临终前接受化疗的概率之间未发现明显规律。

研究设计与样本

  • 全国性、基于登记处的研究,纳入法国2010年至2013年间所有因转移性实体瘤死亡的≥20岁住院患者。

主要发现

  • 共纳入279846例因转移性癌症死亡的住院患者。
  • 临终前1个月内19.5%接受化疗,其中最后2周内11.3%。
  • 女性(OR=0.96,95%CI=0.93-0.98)、年龄每增加10岁(OR=0.70,95%CI=0.69-0.71)及慢性合并症数量更多(OR=0.83,95%CI=0.82-0.84)与较低化疗率独立相关。
  • 化疗敏感肿瘤患者临终前1个月内接受化疗的统计可能性更高(OR=1.21,95%CI=1.18-1.25),但该关联主要由睾丸和卵巢肿瘤驱动。
  • 与大学医院相比,在营利性诊所/医院(OR=1.40,95%CI=1.34-1.45)或综合癌症中心(OR=1.43,95%CI=1.36-1.50)死亡者更可能接受化疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Use of chemotherapy near the end of life in patients with metastatic cancer is often ineffective and toxic. Data about the factors associated with its use remain scarce, especially in Europe. METHODS: Nationwide, register-based study including all hospitalized patients aged ≥20 years who died from metastatic solid tumors in France between 2010 and 2013. RESULTS: A total of 279 846 hospitalized patients who died from metastatic cancer were included. During the last month before death, 19.5% received chemotherapy (including 11.3% during the last 2 weeks). Female sex (OR= 0.96, 95% CI= 0.93-0.98), older age (OR= 0.70, 95% CI= 0.69-0.71 for each 10-year increase) and higher number of chronic comorbidities (OR= 0.83, 95% CI= 0.82-0.84) were independently associated with lower rates of chemotherapy. Although patients with chemosensitive tumors were statistically more likely to receive chemotherapy during the last month before death (OR= 1.21, 1.18-1.25), this association was mostly fueled by testis and ovary tumors and we found no obvious pattern between the expected chemosensitivity of different cancers and the rates of chemotherapy use close to death. Compared with university hospitals, patients who died in for-profit clinics/hospital (OR= 1.40, 95% CI= 1.34-1.45), or comprehensive cancer centers (OR= 1.43, 95% CI= 1.36-1.50) were more likely to receive chemotherapy. Finally, high-volume centers and hospitals without palliative care units reported greater-than-average rates of chemotherapy near the end of life. CONCLUSION: among hospitalized patients with cancer, young individuals, treated in comprehensive cancer centers or in high-volume centers without palliative care units were the most likely to receive chemotherapy near the end of life. We found no evident pattern between the expected chemosensitivity of different cancers and the probability for patients to receive chemotherapy close to death.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Rochigneux P, Raoul JL, Beaussant Y, et al. Use of chemotherapy near the end of life: what factors matter? Ann Oncol. 2017. PMID: 27993817. doi:10.1093/annonc/mdw654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。